Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.
+ 1 more risk
Flawless balance sheet with limited growth.
Share Price & News
How has Aptinyx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APTX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: APTX underperformed the US Biotechs industry which returned 27.3% over the past year.
Return vs Market: APTX exceeded the US Market which returned 9.9% over the past year.
Price Volatility Vs. Market
How volatile is Aptinyx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAptinyx Inc. (NASDAQ:APTX) Just Reported And Analysts Have Been Cutting Their Estimates
3 weeks ago | Simply Wall StNeed To Know: Aptinyx Inc. (NASDAQ:APTX) Insiders Have Been Buying Shares
2 months ago | Simply Wall StAptinyx Inc. (NASDAQ:APTX) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Is Aptinyx undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate APTX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate APTX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: APTX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: APTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APTX is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.7x).
How is Aptinyx forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APTX's revenue (45.3% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: APTX's revenue (45.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APTX's Return on Equity is forecast to be high in 3 years time
How has Aptinyx performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APTX is currently unprofitable.
Growing Profit Margin: APTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APTX is unprofitable, and losses have increased over the past 5 years at a rate of -29.6% per year.
Accelerating Growth: Unable to compare APTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: APTX has a negative Return on Equity (-45.23%), as it is currently unprofitable.
How is Aptinyx's financial position?
Financial Position Analysis
Short Term Liabilities: APTX's short term assets ($126.1M) exceed its short term liabilities ($4.6M).
Long Term Liabilities: APTX's short term assets ($126.1M) exceed its long term liabilities ($234.0K).
Debt to Equity History and Analysis
Debt Level: APTX is debt free.
Reducing Debt: APTX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: APTX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 23.4% each year.
What is Aptinyx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Norbert Riedel (61yo)
Dr. Norbert G. Riedel, Ph.D., serves as Board Member at TRACT Therapeutics, Inc. He serves as Chairman of Eton Pharmaceuticals, Inc., since September 2018 and serves as Industry Advisor at Agent Capital, L ...
CEO Compensation Analysis
Compensation vs Market: Norbert's total compensation ($USD5.64M) is above average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Norbert's compensation has been consistent with company performance over the past year.
|CFO & Chief Business Officer||2.33yrs||US$2.12m||0.62% $1.0m|
|Chief Operating Officer||1.25yrs||US$2.12m||0.020% $33.0k|
|Vice President of Finance & Accounting and Controller||1.25yrs||no data||no data|
|Senior Vice President of Human Resources & Administration||1.25yrs||no data||no data|
|Director of Corporate Development||no data||no data||no data|
|Senior Scientific Advisor||0.83yr||US$497.86k||no data|
|Senior Vice President - Clinical Development||1.42yrs||no data||no data|
|Senior Vice President of Medical & Pharmacovigilance||0.42yr||no data||no data|
Experienced Management: APTX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Independent Director||4.92yrs||US$131.05k||no data|
|Independent Chairman of the Board||0.083yr||US$137.55k||0.21% $343.0k|
|Independent Director||2.5yrs||US$136.05k||no data|
|Independent Director||2.08yrs||US$141.05k||0.33% $538.3k|
|Independent Director||0.75yr||US$182.91k||0.0048% $7.8k|
|Independent Director||1.08yrs||US$215.38k||0.27% $451.3k|
Experienced Board: APTX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36%.
Aptinyx Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aptinyx Inc.
- Ticker: APTX
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$164.817m
- Shares outstanding: 45.66m
- Website: https://www.aptinyx.com
Number of Employees
- Aptinyx Inc.
- 909 Davis Street
- Suite 600
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|APTX||NasdaqGS (Nasdaq Global Select)||COM||US||USD||No data|
|APTX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2018|
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/02 05:16|
|End of Day Share Price||2020/06/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.